Kancera to present at the 2012 BIO International Convention
The BIO International Convention is the largest and most important annual gathering of the biotech and pharmaceutical industry. Kancera has been selected to present the company and its oncology programs at the convention’s Business Forum. The Business Forum is arranged to promote business partnerships and is attended by a global audience of investors and industry CEOs and licensing executives representing over 2,500 companies. The presentation will be at 08:30 a.m. EDT on June 20th.
Information about the convention is available at www.convention.bio.org
About Kancera AB (publ)
Kancera is engaged in drug development that takes its start in new treatment concepts and ends with a candidate drug. Kancera is currently developing medicines for the treatment of both leukemia and solid tumors that interferes with survival signaling and nutrient metabolism within the cancer cell. Kancera is also developing stem cell-based cancer models to study the candidate molecules before testing in humans. Kancera operates in Stockholm and employs approximately 20 people. The share is traded on the NASDAQ OMX First North and the number of shareholders is about 1500. Remium AB is Certified Adviser to Kancera.
For additional information, please contact:
Thomas Olin, CEO: Tel +46 735 20 40 01
Kancera AB (publ)
Karolinska Institutet Science Park
SE 171 48 Solna
Please visit the company’s website www.kancera.comBack